Peptidomics of Urine and Other Biofluids for Cancer Diagnostics
Open Access
- 1 August 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 60 (8) , 1052-1061
Abstract
BACKGROUND: Cancer is a leading cause of death worldwide. The low diagnostic sensitivity and specificity of most current cancer biomarkers make early cancer diagnosis a challenging task. The comprehensive study of peptides and small proteins in a living system, known as “peptidomics,” represents an alternative technological approach to the discovery of potential biomarkers for the assessment of a wide variety of pathologies. This review examines the current status of peptidomics for several body fluids, with a focus on urine, for cancer diagnostics applications. CONTENT: Several studies have used high-throughput technologies to characterize the peptide content of different body fluids. Because of its noninvasive collection and high stability, urine is a valuable source of candidate cancer biomarkers. A wide variety of preanalytical issues concerning patient selection and sample handling need to be considered, because not doing so can affect the quality of the results by introducing bias and artifacts. Optimization of both the analytical strategies and the processing of bioinformatics data is also essential to minimize the false-discovery rate. SUMMARY: Peptidomics-based studies of urine and other body fluids have yielded a number of biomolecules and peptide panels with potential for diagnosing different types of cancer, especially of the ovary, prostate, and bladder. Large-scale studies are needed to validate these molecules as cancer biomarkers.Keywords
This publication has 75 references indexed in Scilit:
- An international assessment of ovarian cancer incidence and mortalityGynecologic Oncology, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- The Long Journey of Cancer Biomarkers from the Bench to the ClinicClinical Chemistry, 2013
- Screening for Prostate CancerNew England Journal of Medicine, 2011
- CA 15-3: Uses and limitation as a biomarker for breast cancerClinica Chimica Acta, 2010
- Clinical proteomics: A need to define the field and to begin to set adequate standardsProteomics – Clinical Applications, 2007
- The blood peptidome: a higher dimension of information content for cancer biomarker discoveryNature Reviews Cancer, 2006
- Repetitive Fragmentation Products of Albumin and α1-Antitrypsin in Glomerular Diseases Associated with Nephrotic SyndromeJournal of the American Society of Nephrology, 2006
- Peptides in body fluids and tissues as markers of diseaseExpert Review of Molecular Diagnostics, 2005
- Clinical proteomics: Written in bloodNature, 2003